U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C16H13O3.Na
Molecular Weight 276.2624
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of KETOPROFEN SODIUM

SMILES

[Na+].CC(C([O-])=O)C1=CC=CC(=C1)C(=O)C2=CC=CC=C2

InChI

InChIKey=OAPDLBHLMVYMCW-UHFFFAOYSA-M
InChI=1S/C16H14O3.Na/c1-11(16(18)19)13-8-5-9-14(10-13)15(17)12-6-3-2-4-7-12;/h2-11H,1H3,(H,18,19);/q;+1/p-1

HIDE SMILES / InChI

Description

Dexketoprofen is a nonsteroidal anti-inflammatory drug (NSAID), manufactured by Menarini under the tradename Keral. Dexketoprofen is indicated for short-term treatment of mild to moderate pain, including dysmenorrhoea. Dexketoprofen works by blocking the action of a substance in the body called cyclo-oxygenase, which is involved in the production of chemicals in the body called prostaglandins. Prostaglandins are produced in response to injury or certain diseases and would otherwise go on to cause swelling, inflammation, and pain. By blocking cyclo-oxygenase, dexketoprofen prevents the production of prostaglandins and therefore reduces inflammation and pain. Along with peripheral analgesic action, it possesses central analgesic action. Dexketoprofen may cause dizziness, and patients should not, therefore, drive or operate heavy machinery or vehicles until they are familiar with how dexketoprofen affects them. Concomitant use of alcohol and other sedatives may potentiate this effect. In a small subset of individuals, the dizziness may be intolerable and require the transition to an alternative treatment.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
1.9 nM [IC50]
27.0 nM [IC50]
50.0 nM [IC50]
0.52 µM [IC50]
0.019 µM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Keral
Primary
Keral
Primary
Keral
Primary
KETOPROFEN
Primary
KETOPROFEN
Primary
KETOPROFEN
Primary
KETOPROFEN

Cmax

ValueDoseCo-administeredAnalytePopulation
10.1 μg/mL
100 mg single, oral
KETOPROFEN plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
21.91 μg × h/mL
100 mg single, oral
KETOPROFEN plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
1.13 h
100 mg single, oral
KETOPROFEN plasma
Homo sapiens

Doses

AEs

Overview

CYP3A4CYP2C9CYP2D6hERG

Drug as perpetrator​

Drug as victim

PubMed

Sample Use Guides

In Vivo Use Guide
Rheumatoid Arthritis and Osteoarthritis: 75 mg three times or 50 mg four times a day. The recommended maximum daily dose of ketoprofen capsules is 300 mg/day. Pain and Dysmenorrhea: 25 to 50 mg every 6 to 8 hours as necessary.
Route of Administration: Oral
In Vitro Use Guide
5 mM Ketoprofen (mouse isolated epidermal cells)